Femasys (NASDAQ:FEMY) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Femasys (NASDAQ:FEMY) posted its quarterly earnings results on Tuesday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04), Zacks reports. The business had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%.

Femasys Stock Down 4.9 %

Shares of NASDAQ FEMY opened at $0.98 on Friday. The firm has a market cap of $22.44 million, a price-to-earnings ratio of -1.21 and a beta of -2.83. Femasys has a 1 year low of $0.73 and a 1 year high of $2.40. The company has a debt-to-equity ratio of 0.86, a quick ratio of 5.93 and a current ratio of 3.94. The stock’s 50-day simple moving average is $1.16 and its 200-day simple moving average is $1.15.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on FEMY. Chardan Capital decreased their price target on Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Femasys in a research report on Tuesday.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.